A. TNBC accounts for over 50% of all breast cancer cases B. TNBC is more aggressive, has a higher rate of recurrence, and is associated with worse outcomes than other breast cancer subtypes C. TNBC is more commonly found in older white women than in other age and ethnic groups D. TNBC rarely metastasizes to the lungs or brain E. Unsure

A. Talazoparib B. Capecitabine C. Pembrolizumab D. Atezolizumab + nab-paclitaxel E. Unsure

A. Olaparib B. Pembrolizumab C. Atezolizumab + nab-paclitaxel D. Carboplatin E. Unsure

A. Fatigue, nausea, hand-foot syndrome, and myelosuppression B. Fatigue, nausea, diarrhea, and myelosuppression C. Fatigue, constipation, myelosuppression, and peripheral neuropathy D. Nausea, diarrhea, hyperglycemia, and peripheral neuropathy E. Unsure

A. Overall survival was significantly extended in the intent-to-treat (ITT) population, including both PD-L1–positive and –negative tumors B. In PD-L1–positive tumors, overall survival was approximately the same for atezolizumab + nab- paclitaxel and placebo + nab-paclitaxel C. The progression-free survival benefit was observed in both PD-L1–positive and –negative tumors D. There was no clinical benefit with the addition of atezolizumab to nab-paclitaxel in PD-L1–negative tumors E. Unsure

A. It is approved by the United States Food and Drug Administration as first-line treatment of mTNBC, regardless of PD-L1 status B. Premedication with acetaminophen, H1 and H2 antagonists, and anti-emetics, including dexamethasone and a 5HT-3 antagonist, is recommended C. It has a low incidence of neutropenia D. It is considered an immune checkpoint inhibitor E. Unsure

A. Pembrolizumab + chemotherapy significantly improved progression-free survival (PFS) compared with chemotherapy alone as first-line therapy in patients with metastatic TNBC (mTNBC) (PD-L1 CPS ≥10) B. PFS was not improved with the addition of pembrolizumab in the PD-L1 CPS ≥1 group C. Grade 3–5 treatment-related adverse event rates were significantly higher in the pembrolizumab arm D. The chemotherapy studied in the trial included eribulin, paclitaxel, and nab-paclitaxel E. Unsure

A. Review medications to identify patients who may or may not be a candidate for immune checkpoint inhibitor therapy B. Counsel patients to aid in managing patient expectations, encourage adherence, and facilitate early detection of adverse events C. Facilitate insurance appeals and peer-to-peer conversations D. Educate clinicians that most patients taking olaparib have limited nausea and vomiting and that anti-emetic prophylaxis is not needed E. Unsure